Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
« Previous Article | Table of Contents
Circulation. 2004;109:III-50-III-57
doi: 10.1161/01.CIR.0000131519.15067.1f
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bellosta, S.
Right arrow Articles by Corsini, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bellosta, S.
Right arrow Articles by Corsini, A.

(Circulation. 2004;109:III-50 – III-57.)
© 2004 American Heart Association, Inc.

Atherosclerosis: Evolving Vascular Biology and Clinical Implications

Safety of Statins

Focus on Clinical Pharmacokinetics and Drug Interactions

Stefano Bellosta, PhD; Rodolfo Paoletti, MD, PhD; Alberto Corsini, PhD

From the Department of Pharmacological Sciences, University of Milan, Milan, Italy.

Correspondence to Alberto Corsini, Department of Pharmacological Sciences, University of Milan, via Balzaretti 9, 20133 Milan, Italy. E-mail Alberto.Corsini{at}unimi.it

Statin monotherapy is generally well tolerated, with a low frequency of adverse events. The most important adverse effects associated with statins are myopathy and an asymptomatic increase in hepatic transaminases, both of which occur infrequently. Because statins are prescribed on a long-term basis, however, possible interactions with other drugs deserve particular attention, as many patients will typically receive pharmacological therapy for concomitant conditions during the course of statin treatment. This review summarizes the pharmacokinetic properties of statins and emphasizes their clinically relevant drug interactions.


Key Words: drug interactions • fibrates • rhabdomyolysis • safety • statins




This article has been cited by other articles:


Home page
 AMERICAN JOURNAL OF LIFESTYLE MEDICINEHome page
T. L. Lenz
Are Physically Active Individuals Taking Statins at Increased Risk for Myopathy?
American Journal of Lifestyle Medicine, July 1, 2009; 3(4): 287 - 289.
[Abstract] [PDF]

Home page
 Sports Health: A Multidisciplinary ApproachHome page
A. Yates, J. Norwig, J. C. Maroon, J. Bost, J. P. Bradley, M. Duca, D. A. Wecht, R. Grove, A. Iso, I. Cobb, et al.
Evaluation of Lipid Profiles and the Use of Omega-3 Essential Fatty Acid in Professional Football Players
Sports Health: A Multidisciplinary Approach, January 1, 2009; 1(1): 21 - 30.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
A. S. Go, W. Y. Lee, J. Yang, J. C. Lo, and J. H. Gurwitz
Statin therapy and risks for death and hospitalization in chronic heart failure.
JAMA, November 1, 2006; 296(17): 2105 - 2111.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
M. A. Mittleman
A 39-year-old woman with hypercholesterolemia.
JAMA, July 19, 2006; 296(3): 319 - 326.
[Abstract] [Full Text] [PDF]


Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search
Copyright © 2004 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited.